for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amarin Corporation plc (ADR)

AMRN.O

Latest Trade

6.94USD

Change

0.18(+2.59%)

Volume

2,990,632

Today's Range

6.85

 - 

7.03

52 Week Range

3.95

 - 

26.12

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.76
Open
6.90
Volume
2,990,632
3M AVG Volume
326.79
Today's High
7.03
Today's Low
6.85
52 Week High
26.12
52 Week Low
3.95
Shares Out (MIL)
390.65
Market Cap (MIL)
2,559.65
Forward P/E
-63.24
Dividend (Yield %)
--

Latest Developments

More

Amarin Reports Q1 2020 Financial Results

Amarin Corp PLC Files For Potential Mixed Shelf Offering Size Not Disclosed - SEC Filing

Amarin Corp Qtrly Shr $0.02

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Amarin Corporation plc (ADR)

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Industry

Biotechnology & Drugs

Contact Info

Gemini House, Bartholomews Walk

FK7 9JQ

Ireland

+353.1.6699020

http://www.amarincorp.com/

Executive Leadership

Lars G. Ekman

Non-Executive Independent Chairman of the Board

John F. Thero

President, Chief Executive Officer, Director

Michael Wayne Kalb

Chief Financial Officer, Senior Vice President, Assistant Secretary

Joseph T. Kennedy

Executive Vice President, General Counsel, Secretary, Strategic Initiatives

Stephen B. Ketchum

President - Research and Development, Senior Vice President, Chief Scientific Officer

Key Stats

2.23 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.2K

2018

0.2K

2019

0.4K

2020(E)

0.7K
EPS (USD)

2017

-0.250

2018

-0.390

2019

-0.070

2020(E)

-0.105
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.00
Price To Book (MRQ)
4.26
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
6.31
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-4.55
Return on Equity (TTM)
-2.89

Latest News

Latest News

BRIEF-Amarin Plans To Increase Vascepa Promotion And Education

* AMARIN PLANS TO INCREASE VASCEPA® (ICOSAPENT ETHYL) PROMOTION AND EDUCATION

BRIEF-Amarin Supports Trial To Investigate Effects Of Vascepa In Treatment Of COVID-19

* AMARIN SUPPORTS TRIAL TO INVESTIGATE THE EFFECTS OF VASCEPA® (ICOSAPENT ETHYL) IN THE TREATMENT OF COVID-19 Source text for Eikon: Further company coverage:

BRIEF-Amarin Reports Q1 2020 Financial Results

* AMARIN REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS

BRIEF-Amarin Corp Reports $150 Mln Total Revenue For 3 Months Ended March 31

* BASED ON A PRELIMINARY ESTIMATE, ITS TOTAL REVENUE, NET FOR THREE MONTHS ENDED MARCH 31 WAS APPROXIMATELY $150 MILLION

Amarin loses patent lawsuit on main drug, shares tumble

Shares of Amarin Corp plunged nearly 70% on Tuesday after the drugmaker lost a major U.S. patent battle for its heart drug Vascepa, opening the door for generic competition to its main revenue contributor.

BRIEF-HLS Therapeutics Comments On U.S. District Court Decision On Amarin Patents

* HLS THERAPEUTICS COMMENTS ON U.S. DISTRICT COURT DECISION ON AMARIN PATENTS

IN BRIEF: Amarin plunges after surprise patent ruling on heart drug

A judge ruled on Monday that patents covering the Amarin Corporation plc heart drug Vascepa were invalid, giving two generic drug companies an opening to sell their own low-cost versions years earlier than industry observers had expected.

BRIEF-Amarin Says Will Continue With Promotional Efforts For Vascepa In Treating Indicated Patients At High Risk Of Cardiovascular Events

* AMARIN CORPORATION - WILL PURSUE ALL AVAILABLE REMEDIES, INCLUDING AN APPEAL OF COURT'S DECISION

BRIEF-Amarin Says Eicosapentaenoic Acid Levels From Vascepa In Reduce-It® Strongly Correlated With Cardiovascular Outcomes

* EICOSAPENTAENOIC ACID (EPA) LEVELS FROM VASCEPA® (ICOSAPENT ETHYL) IN REDUCE-IT® STRONGLY CORRELATED WITH CARDIOVASCULAR OUTCOMES

BRIEF-Amarin Corp PLC Files For Potential Mixed Shelf Offering Size Not Disclosed - SEC Filing

* AMARIN CORPORATION PLC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2PtiTfe) Further company coverage:

BRIEF-Amarin Corp Qtrly Shr $0.02

* QTRLY SHR $0.02; QTRLY ADJ. SHR $0.04; QTRLY NET REV $143.3 MLN, UP 85%

Amarin beats quarterly revenue estimates on strong Vascepa uptake

Amarin Corp Plc <AMRN.O> beat estimates for fourth-quarter revenue on Tuesday, helped by strong demand for its fish-oil derived therapy Vascepa that recently won U.S. approval for expanded heart benefit claims.

FDA says Amarin can market fish-oil derived therapy for reducing heart attack risk

U.S. health regulators on Friday approved expanding the heart benefit claims Amarin Corp can make in promoting its drug Vascepa to include reducing the risk of heart attacks and strokes in high-risk patients, opening a multibillion-dollar market opportunity.

FDA panel unanimously backs expanding use of Amarin's heart drug Vascepa

A panel of experts to the U.S. FDA recommended allowing Amarin Corp Plc's fish-oil derived drug to be used as an add-on therapy for reducing the chance of heart attacks and strokes in high-risk patients with cardiovascular disease.

FDA panel unanimously backs expanding use of Amarin's heart drug Vascepa

A panel of experts to the U.S. FDA on Thursday recommended allowing Amarin Corp Plc's fish-oil derived drug to be used as add-on therapy for reducing the chance of heart attacks and strokes in high-risk patients with cardiovascular disease.

Amarin surges as fish-oil drug receives largely positive FDA review

Amarin Corp Plc's fish oil-derived drug received a largely positive review from FDA staffers on Tuesday, dispelling investor fears that the company's choice of placebo in its trial could challenge the approval of its potential blockbuster.

Shares of Amarin jump after FDA staff review on fish-oil drug

U.S. Food and Drug Administration staffers reviewing Amarin Corp Plc's fish oil-derived drug said on Tuesday the agency's tests were inconclusive on whether the use of mineral oil as placebo in the company's trial could have impacted results.

Amarin's Vascepa cuts occurrence of serious heart problems 30 percent: study

A high dose of Amarin Corp's Omega-3 drug Vascepa significantly reduced the occurrence of first and subsequent heart attacks, strokes and other serious heart problems in high-risk patients already taking cholesterol medication by even more than initially reported, according...

BRIEF-Amarin Corporation Reports Q1 GAAP Loss Per Share $0.08

* REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS

BRIEF-Amarin estimates net product revenue for Q1 to be about $43 mln

* AMARIN UPDATES FIRST QUARTER REVENUE GUIDANCE, REITERATES FULL YEAR GUIDANCE AND UPDATES ON REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY PROGRESS AND VASCEPA PROMOTION INITIATIVES

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up